JERUSALEM, November 10, 2010 /PRNewswire-FirstCall/ -- Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company will be presenting its technology at the annual Medica 2010 Exhibition in Germany on November 16-19.
Medica is the world's largest annual exhibition in the medical sector, with over 135,000 participants and 4,000 exhibitors arriving from over 100 nations.
The conference attracts users of medical products and services including surgical equipment, implantable devices, physiotherapy products, communications systems and diagnostic equipment. Medica is supported by the Compamed exhibition, which focuses on the suppliers of components and systems to the Medical Technology industry.
"Our participation in the Medica conference is part of our strategic business development initiative to increase awareness about the number of lives that can be saved using advanced locking-device technology on syringes," said Jacob Elhadad, CEO of Medisafe 1 Technologies. "MediSafe 1 Technologies is well positioned to enter the multi-billion dollar medical supply industry, with a particular focus on hospitals, nursing homes and rehabilitation centers worldwide."
About Medisafe 1 Technologies
Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.
This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. Medisafe 1 Technologies Corp. public filings may be viewed at http://www.sec.gov.
Contact: Jacob Elhadad CEO +972-524440000 Jacob.email@example.com
|SOURCE Medisafe 1 Technologies Corp.|
Copyright©2010 PR Newswire.
All rights reserved